FDA approves Reclast (zoledronic acid) for osteoporosis in postmenopausal women

Links shared publicly online about this topic.

  • 2,001
    total visits

FDA approves Reclast (zoledronic acid) for osteoporosis in postmenopausal women

news-medical.net

Reclast (zoledronic acid) Injection has been approved by the US Food and Drug Administration (FDA) as the first and only therapy to prevent postmenopausal osteoporosis for two years with a single dose. Reclast is already approved as a once-yearly infusion for the treatment of postmenopausal osteoporosis.

View full resource at news-medical.net

Tags: Osteoporosis, Diet and Nutrition, Drug, Women's Health, FDA, News

  • Share

Most Recently Shared on June 1, 2009 at 2:02 pm By:

Osteoporosis_nt News-Medical.Net

Osteoporosis News: FDA approves Reclast (zoledronic acid) for osteoporosis in postmenopausal w.. http://tinyurl.com/ktja8m

3 years ago...

Reclast approved for biennial dosing regimen to prevent female osteoporosis - MPR

empr.com — “The FDA has approved Reclast (zoledronic acid, from Novartis) injection for the prevention of osteoporosis in women for two years with a single dose.View full resource at empr.com

  • View Related
  • Share

Most Recently Shared on June 2, 2009 at 3:08 pm By:

eMPR MPR Medical Publisher

MPR News: Reclast approved for biennial dosing regimen to prevent female osteoporosis: The FDA has appr.. http://tinyurl.com/lk629z

3 years ago...

Medical News: Zoledronic Acid Okayed for Two-Year Treatment of Osteoporosis - in Endocrinology, Osteoporosis from MedPage Today

medpagetoday.com — “WASHINGTON -- The FDA has approved zoledronic acid (Reclast) to prevent postmenopausal osteoporosis for two years with a single injection.View full resource at medpagetoday.com

  • View Related
  • Share

Most Recently Shared on June 1, 2009 at 11:41 pm By:

MedicalNews Medical News Health News

FDA• Zoledronic Acid Okayed for Two-Year Treatment of Osteoporosis http://tinyurl.com/knyv8p

3 years ago...

FDA approves Reclast to prevent osteoporosis in postmenopausal women with convenient less frequent dosing

novartis.com — “Basel, June 1, 2009 - Reclast (zoledronic acid 5 mg) Injection[*] has been approved by the US Food and Drug Administration (FDA) as the first and only therapy to prevent postmenopausal osteoporosis for two years with a single dose[1]. Reclast, or Aclasta as it is known outside the US, is already approved in more than 80 countries including the US and EU as a once-yearly infusion for the treatment of postmenopausal osteoporosis[1],[4].View full resource at novartis.com

  • View Related
  • Share

Most Recently Shared on June 1, 2009 at 5:36 am By:

Novartis Novartis Pharma

FDA approves Reclast® to prevent osteoporosis in postmenopausal women with convenient less frequent dosing: http://twurl.nl/po8fan

3 years ago...

Advertisement